Biogen Inc header image

Biogen Inc

BIIB

Equity

ISIN null / Valor 1720684

NASDAQ (2026-10-29)
USD 249.65+2.29%

Biogen Inc
UMushroom community rating:

star star star star star
4.40 5 votes No rating yet
NegativeNeutralPositive

About company

Biogen Inc is a prominent biotechnology company that focuses on developing therapies for a range of complex and debilitating diseases. Established in 1978, the company has made significant advancements in the field, particularly in neurology, neuropsychiatry, specialized immunology, and rare diseases. Biogen is known for its innovative treatments for conditions such as multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease. The company is dedicated to serving humanity through scientific research and is committed to creating a healthier, more sustainable, and equitable world.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

68.8%1Y
6.45%3Y
-6.39%5Y

Performance

34.9%1Y
30.8%3Y
33.3%5Y

Volatility

Market cap

36903 M

Market cap (USD)

Daily traded volume (Shares)

1,157,855

Daily traded volume (Shares)

1 day high/low

151.14 / 148.23

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.40

5 votes
Performance:
starstarstarstarstar
4.20
Innovation:
starstarstarstarstar
4.80
Society:
starstarstarstarstar
4.20
Nature:
starstarstarstarstar
4.00
Tonia Zimmermann
Switzerland, 13 Jun 2023
star star star star star
Not just leading in supporting Alzheimer patience, but also pioneering in digital health.
Igor Jovicic
Switzerland, 13 Jun 2023
star star star star star
A company that seems to be making an impact in the biotech sector!
Luba Schoenig
Switzerland, 13 Jun 2023
star star star star star
FDA Advisory Committee recommended the Food and Drug Administration to approve Leqembi, an Alzheimer's drug from Biogen and its Japanese partner Eisai.

EQUITIES OF THE SAME SECTOR

Trupanion Inc
Trupanion Inc Trupanion Inc Valor: 24738737
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.27%USD 30.19
Roche Holding Ltd
Roche Holding Ltd Roche Holding Ltd Valor: 1203211
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.09%CHF 409.40
Venture Life Group PLC
Venture Life Group PLC Venture Life Group PLC Valor: 23084203
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.26%GBP 0.68
Omnicell Inc
Omnicell Inc Omnicell Inc Valor: 1275961
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.59%USD 36.88
Bruker Corp
Bruker Corp Bruker Corp Valor: 1635622
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%USD 62.00
McKesson Corp
McKesson Corp McKesson Corp Valor: 991041
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.12%USD 980.88
Vita 34 AG
Vita 34 AG Vita 34 AG Valor: 2333201
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%EUR 2.79
Embla Medical hf
Embla Medical hf Embla Medical hf Valor: 1060135
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.55%DKK 27.05
Ambea AB
Ambea AB Ambea AB Valor: 36138415
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.50%SEK 183.30
Roivant Sciences Limited
Roivant Sciences Limited Roivant Sciences Limited Valor: 113331044
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.10%USD 37.52